Dainippon Sumitomo Seeks Added Uses For AmBisome Anti-Fungal
This article was originally published in PharmAsia News
Dainippon Sumitomo Pharma has filed for additional indications for its anti-fungal AmBisome (amphotericin). The company is believed to be asking for several additional fungi to be added to the three it now has approval for, but it would not say how many or which. The drug already has Japanese approval for treating aspergillus, candida and cryptococcus. Dainippon applied under a system that could allow approval of the additional uses without being subjected to new clinical trials. (Click here for more - a subscription may be required
You may also be interested in...
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.